The efficacy of hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic pegylated interferon alpha-2b for advanced intrahepatic cholangiocarcinoma

The efficacy of hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic pegylated interferon alpha-2b for advanced intrahepatic cholangiocarcinoma - Combined 5-FU and PEG-IFN alpha-2b therapy for ICC

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000007303

Enrollment

Registered

2012-02-25

Start date

2008-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced intrahepatic cholangiocarcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients were required to have histologically confirmed, unresectable, and measurable ICC. Other eligibility criteria were age &#8805; 18 years, an Eastern Cooperative Oncology Group (ECOG) performance status of 0&#8211;2, platelet count > 0.5 &#61620; 105/&#61549;l, leukocyte count > 2000/&#61549;l, total bilirubin < 3 mg/dl, serum creatinine < 1.5 mg/dl, and successful implantation of an intra-arterial catheter and drug delivery system.

Exclusion criteria

Exclusion criteria: Pregnancy

Design outcomes

Primary

Measure	Time frame
The primary endpoint of interest was the overall response rate	—

Countries

Japan

Outcome results